Study	Total WD (n)	Study Population	Age mean (SD)	Male, n (%)	Mean Age at Diagnosis (SD)	Mean Age at Symptom Onset (SD)	Duration of Disease (yr)	Latency Period in Years (SD)	Medical Treatment, n (%)					Duration of Treatment in Years	Hepatic, n (%)	Neuro-logical, n (%)	Mixed, n (%)	NS, n (%)
									Any	PEN	TRI	Zinc	Combo
Schaefer et al (2016)[@95748]	68	All	36.6 (12.9)	29 (43)	18.5 (11)	16.6 (10.6)	—	2.6 (4.9)	68 (100)	36 (53)	16 (24)	13 (19)	3 (4)	—	38 (56)	7 (10)	10 (15)	—
	39	Female	37.9 (3.5)	0	17.3 (11.3)	16.1 (3.9)	—	2.4 (5.1)	39 (100)	17 (44)	12 (31)	9 (23)	1 (2)	—	21 (54)	4 (10)	4 (10)	—
	29	Male	35.2 (12.2)	29 (100)	20.6 (10.6)	17.8 (12.7)	—	3.2 (3.1)	29 (100)	19 (66)	4 (14)	4 (14)	2 (6)	—	17 (59)	3 (10)	6 (21)	—
	37	Pencilamine	—	19 (51)	13.1 (5.3)	—	—	—	37 (100)	37 (100)	0	0	0	12.6 (12.1)	26 (70)	2 (5)	6 (16)	—
	16	Trientine	—	4 (25)	19.6 (9.7)	—	—	—	16 (100)	0	16 (100)	0	0	8.1 (5.6)	7 (44)	2 (12)	2 (12)	—
	13	Zinc	—	4 (31)	24.2 (13.9)	—	—	—	13 (100)	0	0	13 (100)	0	8.6 (4.4)	4 (31)	2 (15)	2 (15)	—
	2	Combo	—	2 (100)	14.4 (1)	—	—	—	2 (100)	0	0	2 (100)	0	12.2	1 (50)	1 (50)	0	—
Carta et al (2012)[@95749]	23	Cases	42.02 (12.52)	9 (39.1)	30.19c (18.28)	—	—	—	—	—	—	—	—	—	—	—	—	—
	92	Controls	42.35 (10.29)	36 (39.1)	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Svetel et al (2011)[@95750]	60	All	36.8 (11.0)	36 (60)	—	24 (8.3)	—	22.1 (32.6)a	60 (100)	39 (65)	1 (1.7)	8 (13.3)	12 (20)	11.3 (8.2)	19 (31.7)	41 (68.3)	0	—
Aggarwal et al (2009)[@95752]	30	All	17 (7-40)b	17	—	—	—	—	30 (100)	30 (100)	—	—	—	—	—	—	—	8
Komal Kumar et al (2007)[@95753]	30	All	27.97 (11.16)	23	20.3 (10.7)	16.8 (7.1)	11.08 (9.31)	—	30 (100)	—	—	—	—	9.2 (6.4)	1	27d	2	—
Sutcliffe et al (2003)[@95751]	21	All	16.5c (8-41)b	6	—	—	—	—	—	—	—	—	—	—	21 (100)	—	—	—
Camarata et al (2021)[@95754]	62	All	41 (30-56)b	36 (58.06)	19 (11-25)b	—	—	—	—	—	—	—	—	19.5(7-35)b	12 (19.67)	50 (80.65)	—	—